Brief: Paion: initiation of Remimazolan U.S. clinical safety trial in patiens undergoing colonoscopy
Dec 1 (Reuters) - Paion AG PA8G.DE :
* Announces initiation of U.S. clinical safety trial of
Remimazolam in high risk patients undergoing colonoscopy
* Completion of patient recruitment is expected in 2016
Source text for Eikon: ID:nEQ1QnYJha
Further company coverage: PA8G.DE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 698 39 20;))
Recent news on PAION AG
See all newsBrief: Paion AG To Issue Approx 4.8 Mln Shares In Capital Increase With Subscription Rights
Brief: Paion AG Reports Developments On Commercial Activities In Europe
Brief: Paion Q1 EBITDA Up At EUR 15 Mln
Brief: Paion Grants Exclusive License To Cristália For Development And Commercialization Of Remimazolam In Latin America
Brief: Paion Announces Sebastian Werner As New CFO, Effective 1 June 2022